Exelixis (EXEL) Accounts Payables (2010 - 2026)
Exelixis (EXEL) posted quarterly Accounts Payables of $24.2 million for Q2 2026, down 43.62% year-over-year from $42.8 million in Q2 2025, and down 18.46% quarter-over-quarter from $29.6 million in Q1 2026.
Analysis
Exelixis (EXEL) Accounts Payables (2010 - 2026) Analysis & Trends
Exelixis' Accounts Payables history runs 17 years deep, the most recent figure standing at $24.2 million for Q2 2026.
- In Q2 2026, Accounts Payables fell 43.62% year-over-year to $24.2 million; the TTM figure through Apr 2026 stood at $24.2 million (down 43.62% YoY), while the FY2026 annual figure was $29.6 million, down 22.43% from the prior year.
- Accounts Payables for Q2 2026 stood at $24.2 million, down from $29.6 million in the prior quarter.
- The five-year high for Accounts Payables was $59.3 million in Q3 2024, with the low at $17.3 million in Q2 2022.
- The 5-year median for Accounts Payables is $28.7 million (2024), against an average of $30.6 million.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables jumped 124.23% in 2024, then sank 57.26% in 2025.
- Exelixis' Accounts Payables stood at $32.7 million in 2022, then gained by 3.37% to $33.8 million in 2023, then jumped by 75.64% to $59.3 million in 2024, then tumbled by 57.26% to $25.3 million in 2025, then declined by 4.71% to $24.2 million in 2026.
- Business Quant data shows EXEL's Accounts Payables at $24.2 million in Q2 2026, $29.6 million in Q1 2026, and $25.3 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 167.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 88.42 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 470.30 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 35.57 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 39.06 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 39.06 Mn |
| Apr 3, 2026 | 24.15 Mn |
| Jan 2, 2026 | 29.62 Mn |
| Oct 3, 2025 | 25.35 Mn |
| Jul 4, 2025 | 25.82 Mn |
| Apr 4, 2025 | 42.84 Mn |
| Jan 3, 2025 | 38.19 Mn |
| Sep 27, 2024 | 59.31 Mn |
| Jun 28, 2024 | 28.68 Mn |
| Mar 29, 2024 | 26.07 Mn |
| Dec 29, 2023 | 33.77 Mn |
| Sep 29, 2023 | 26.45 Mn |
| Jun 30, 2023 | 25.99 Mn |
| Mar 31, 2023 | 32.62 Mn |
| Dec 30, 2022 | 32.67 Mn |
| Sep 30, 2022 | 30.57 Mn |
| Jul 1, 2022 | 19.98 Mn |
| Apr 1, 2022 | 17.29 Mn |
| Dec 31, 2021 | 24.26 Mn |
| Oct 1, 2021 | 24.31 Mn |